Normalized claim
Time: 10 x
Accelerated therapeutic molecule discovery timelines by up to 10x
Last evidence check: Jul 22, 2026
Launching Latent Labs: AI in Protein Therapeutics
Use case typeTherapeutics discoveryUpdated Jun 13, 2026
Latent Labs, led by ex-DeepMind scientist Dr. Simon Kohl, emerged as a generative AI service provider specializing in protein design for drug discovery. Using advanced AI, they aim to computationally design therapeutic molecules like antibodies and enzymes, revolutionizing treatments. Partnerships with Microsoft and renowned industry experts further strengthen their mission.
- Organization
- Latent Labs
- Industry
- Pharma
- Location
- United Kingdom
- Published
- February 2025
Reported outcomes
10x
timeTime & speed
Strategic outcomes
New product / capabilityDeveloped generative protein design platformNew business modelOffered AI as a serviceCustomer experience & trustEnabled access without in-house AINew product / capabilityUnlocked previously inaccessible drug targets
Why do we believe this?Outcome claims, sources, and evidence checks
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
- Customer
- Latent Labs
- Provider
- Microsoft
- Maturity
- Unknown
- Linked source
- pharmaphorum
No explicit deployment-stage evidence found.
Customer identity supportedSource describes one deploymentMaturity evidence evaluated
Primary read
Use case focus
Showing 3 of 5
- 1Generative protein design for novel therapeutics
- 2AI-guided optimization of enzyme stability and affinity
- 3Computational de-risking of drug targets
- Traditional drug discovery is slow and costly, often taking 10-15 years to bring a new therapy to market
- Many promising drug targets remain inaccessible due to the complexity of protein design
- Biopharma researchers lack access to advanced AI models for protein engineering
- Existing methods offer low hit rates for desirable therapeutic properties (e.g., affinity, stability)
- High costs and technical barriers for in-house generative AI infrastructure in most pharma companies
- Developed a generative AI platform for de novo protein and antibody design
- Leveraged Azure AI for scalable computational modeling and training
- Provided AI-powered as-a-service solution for biopharma partners
- Recruited interdisciplinary experts from AI and computational biology to drive innovation
Technologies
- Accelerated therapeutic molecule discovery timelines by up to 10x
- Enabled partners to access cutting-edge protein design without in-house AI
- Lowered costs associated with early-stage discovery and molecule optimization
- Supported unlocking of previously undruggable targets for pharma researchers
Sources & evidence1
Evidence: Medium60/100Evidence strength
- Customer explicitly identified
- Independent source available
- Quantified outcome available
- Technical implementation details available
- Recent evidence check available
- Last evidence check: Jul 22, 2026.
Live sourceStill referenced
The case's original source is still reachable.
- Cited source last checked Jun 12, 2026 — ok (0/1 broken).
Measures whether this deployment's public evidence persists — not whether the system is still in production.
Type: News ArticlePublished: Feb 13, 2025Publisher: pharmaphorumEvidence: SecondaryConfidence: Low
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Customer evidence
Provider evidence
Browse the catalog
Was this useful?
Community
Comments
Loading comments...